1-Methyl-1.2-dihydro-pyrazolo<1,5-a>pyridinon-(2) | 60637-28-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 1-Methyl-1.2-dihydro-pyrazolo<1,5-a>pyridinon-(2)
• 英文别名: 1-methyl-pyrazolo[1,5-a]pyridin-2-one；1-methylpyrazolo[1,5-a]pyridin-2(1H)-one；1-methylpyrazolo[1,5-a]pyridin-2-one
• CAS: 60637-28-7
• 化学式: C₈H₈N₂O
• 分子量: 148.164
• InChiKey: PMIBWPFJPXOLQX-UHFFFAOYSA-N

物化性质

• 熔点：
  165-167 °C(Solv: benzene (71-43-2))
• 沸点：
  289.0±23.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吡唑并[1,5-a]吡啶-2(1H)-酮 生成 1-Methyl-1.2-dihydro-pyrazolo<1,5-a>pyridinon-(2)
  参考文献：
  名称：

  OCHI H.; MIYASAKA T.; KANADA K.; ARAKAWA K., BULL. CHEM. SOC. JAP. , 1976, 49, NO 7, 1980-1984

  摘要：

  DOI：

文献信息

• Methods and compositions for treating schizophrenia
  申请人：The Johns Hopkins University

  公开号：US10624875B2

  公开（公告）日：2020-04-21

  The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).

  本发明涉及通过使用突触小泡蛋白2A（SV2A）抑制剂和抗精神病药或它们的药学上可接受的盐、水合物、溶液物、多晶型物的组合来治疗精神分裂症或躁郁症（尤其是躁狂症）的方法和组合物。在某些实施方案中，本发明的方法和组合物用于治疗与精神分裂症或双相情感障碍（尤其是躁狂症）相关的一种或多种阳性和/或阴性症状以及认知障碍。
• Methods and compositions for improving cognitive function
  申请人：The Johns Hopkins University

  公开号：US10806717B2

  公开（公告）日：2020-10-20

  This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.

  本发明涉及治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法和组合物。 特别是，本发明涉及突触小泡糖蛋白 2A (SV2A)抑制剂单独或与丙戊酸钠联合用于治疗与中枢神经系统 (CNS) 紊乱相关的认知损伤，需要治疗或有治疗风险的受试者，包括但不限于具有或有年龄相关认知损伤风险的受试者。
• New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders
  申请人：Kenda Benoit

  公开号：US20100222326A1

  公开（公告）日：2010-09-02

  The present invention relates to new compounds, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
• METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
  申请人：Gallagher Michela

  公开号：US20110212928A1

  公开（公告）日：2011-09-01

  The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis (ALS), and cancer-therapy-related cognitive impairment.
• METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
  申请人：Gallagher Michela

  公开号：US20140206667A1

  公开（公告）日：2014-07-24

  The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).